Page 156 - CW E-Magazine (30-7-2024)

News from Abroad

GROWTH PLANS
CordenPharma pumping in €900-mn to expand peptide

capabilities in US and Europe

CordenPharma, the US-based the construction of a new greenfield
pharma & biotech CDMO and a part facility, with the aim of creating additional
of Astorg, a European private equity peptide capacity to serve customers from
firm, has announced its largest initial early clinical to late-stage commer-
investment to date with plans to spend cial manufacturing. “The new site will be
around €900-mn over the next three located in the heart of Europe, fully-inte-
years at in its US and European site to grated within CordenPharma’s existing
grow its peptide technology platform. facility network,” the company said.

These plans consist of two major “Upon completion, the new con-
expansion initiatives occurring in structions will be fully integrated with-
parallel in the US and Europe, including in its network of cGMP manufacturing
both existing facilities and new con- facilities, along with the dedicated tech-
structions designed and built accord- nical and regulatory support by expert
ing to the pharmaceutical industry’s additional increase in manufacturing teams needed to secure innovators’
most stringent quality and technical trains in the existing facility. supply chains with small to large-scale
standards for short and long peptide fully-integrated services from APIs to
manufacturing, including Biologics The company said the move is in drug products,” the company said in a
License Applications (BLA) require- response to the “rapidly increasing demand press note.
ments. in the diabetes and obesity glucagon-like
peptide 1 (GLP-1) agonist medications The growth plans aim to help the
The US expansion involves bring- market, and comes off the back of multi- company reach the €1-bn sales mark
ing additional peptide capacity to the ple, long-term, multiyear contracts total- for its peptide platform, and around
company’s Colorado site with the ling around €3-bn, with potential upsides”. €1.8-bn total group revenue by 2028.
planned construction of a new large- In the 2023 financial year, the company
scale manufacturing facility, and an The European expansion centres on generated sales of €880-mn.

Catalent completes expansion of clinical supply

facility in Germany

American pharma CDMO, Catalent, to enable timely and cost-effective
has completed expansion of its clinical adaptation and regional supply of clinical
supply facility in Schorndorf, Germany. materials on demand. “The Schorn-
The site, Catalent’s flagship European dorf site plays an important role in the
facility, provides clinical supply ser- strategic focus of the company and our
vices, including packaging, storage and ability to meet customer demand for
distribution. The expansion increases clinical packaging solutions, including
the site’s footprint by 32,000 square temperature-controlled services,” said
feet, adding storage and handling of filling line, as well as a dedicated area Mr. Lorenzo Carletti, President, Clini-
clinical trial supply materials at con- for Catalent’s FastChain demand-led cal Development & Supply, Catalent.
trolled room temperatures between 15- supply service. The FastChain service The site also offers late-stage pharma
25°C. It also creates space in the original is a continuous Good Manufacturing product development and commercial
building to accommodate the instal- Practices (GMP) approach that decou- services, including oral solid dose manu-
lation of a new, fully automatic bottle ples primary from secondary packaging facturing and speciality packaging.

156 Chemical Weekly July 30, 2024

Contents Index to Advertisers Index to Products Advertised